Pharmaceutical Contract Manufacturing Market
The future of the global pharmaceutical contract manufacturing market looks promising with opportunities in the big pharmaceutical, small & medium-sized pharmaceutical, and generic pharmaceutical markets. The global pharmaceutical contract manufacturing market is expected to reach an estimated $408.8 billion by 2035 from $236.8 billion in 2027 with a CAGR of 7.1% from 2027 to 2035. The major drivers for this market are the growing demand for faster drug production & delivery, the rising need for advanced manufacturing technologies, and the increasing outsourcing by pharmaceutical companies to reduce costs.
- Lucintel forecasts that, within the Services category, biologics manufacturing is expected to witness the highest growth over the forecast period due to the increasing demand for biologics production outsourcing.
- Within the end use category, big pharmaceutical is expected to witness the highest growth over the forecast period due to the rising drug development pipelines and biologics investments.
- In terms of regions, APAC is expected to witness the highest growth over the forecast period due to the rapid pharmaceutical manufacturing expansion and cost advantages.
Emerging Trends in Pharmaceutical Contract Manufacturing Market
The pharmaceutical contract manufacturing market is changing from capacity outsourcing to integrated development, commercial production, and reliable supply. Lucintel expects sustained demand from biologics, complex injectables, and smaller biotech companies out to 2027. Also, in 2025, CDMOs further specialized in mammalian-cell, viral-vector and antibody-drug conjugate capabilities, while biologics made up more than 40% of the global pharmaceutical pipelines; therefore, this specialization will attract premium contracts, as the manufactured molecules become more difficult.
- Manufacturing Automation: In the 2025-2027 period, companies will deploy single-use bioreactors and process analytics, and leverage digital batch records. Newer facilities will be designed using 2,000-liter production trains. Automation will increase yield, traceability, and labor productivity over the next five years.
- Regional Supply Diversification: Repeated drug shortages and disruptions in the supply chain have led drug makers to diversify their supply across North America, Europe and Asia. Drug maker investments supported by the CHIPS and Science Act and the EU programs will add capacity through 2027, reducing reliance on single-country sourcing.
- Sustainability: Water use and solvent use in biologics manufacturing has come under increased focus. The use of renewable energy has also increased. In 2025, several companies set goals to become carbon neutral by 2050. Customer focus on sustainability has increased and will continue to do so.
- Integrated Services: Sponsors want integrated services from a single CDMO partner from early development through clinical batches, analytical testing, commercial manufacturing and supply. This reduces the burden of technology transfer between multiple CDMO partners. CDMOs with integrated, end-to-end, manufacturing services will gain larger, more long-term contracts.
During the next 3-5 years, capacity alone will not differentiate leading contract manufacturing organizations (CMOs) from the rest. Leading biologics CMOs will also excel at integrated development and digital manufacturing. Regional drug supply resilience will also increase differentiation.
Recent Developments in the Pharmaceutical Contract Manufacturing Market
The manufacturing of biologics and peptide drugs is reaching the limits of capacity and creating a need for the higher-investment cycle of complex contract manufacturing. This will continue through 2027, as manufacturers strive for regional supply security. Lucintel expects similar trends to continue as sponsors invest in larger, integrated CDMOs.
- Capacity Expansion: Eli Lilly's investment of $3 billion to build an oral-medicine manufacturing site in Virginia (May 2025) demonstrates the strength and commitment of a sponsor to produce both API and finished dosage forms in the U.S., thereby encouraging other sponsors to build geographically diversified sites.
- Biologics Scale-up: In April 2025, when Samsung Biologics completes Plant 5, it will add 180,000 liters and bring its total capacity to 784,000 liters. This will create further competition in the market among CDMOs catering to late stage monoclonal antibodies.
- Peptide Manufacturing: In May 2024, Novo Nordisk committed approximately $6 billion to expand API production in Denmark, with the capacity expected to be available from 2025 to 2027. With continued strong demand for GLP-1, CDMO investment in peptide manufacturing and supply will increase.
- Consolidation and Integration: In December 2024, Thermo Fisher Scientific closed its $4.5 billion acquisition of Catalent. Thermo Fisher is integrating Catalent and this is shifting customer preferences to provide more integrated services from development to biologics and commercial manufacturing.
- Regionalization: In 2025, Fujifilm Diosynth Biotechnologies will complete its $1.2 billion expansion to large scale biologics manufacturing in the US. New regional capacity will increase competition and reduce cross-border reliance for biologics manufacturing.
In the next five years, biologics and peptide programs will demand significant sponsor investment and consolidate capacity among a limited number of suppliers. CDMOs must have processing capacity and execution speed to win contracts. While sponsors will further integrate their supplier base, capacity alone will not win contracts; dependable execution and quality systems will be the most important differentiators.
Strategic Growth Opportunities in the Pharmaceutical Contract Manufacturing Market
Pharmaceutical contract manufacturing is gaining commercial importance as drug pipelines shift toward complex modalities and sponsors reduce their exposure to fixed assets. 2024-2026 Biologics and shortage funding is widening outsourcing budgets. Capacity specialization and execution of quality are the key differentiators, says Lucintel.
- Advanced Biologics and Modalities: CDMOs can expand into antibody drug conjugates and other cell and messenger RNA therapeutics. In January 2025, Samsung Biologics reported a backlog in excess of $20 billion. This will lead the market as sponsors outsource difficult, high-tech programs.
- Sterile Injectable Capacity: The shortage of fill-finish capacity allows for the establishment of high-end, specialty facilities for GLP-1 products, vaccines, and oncology products. In March 2025, Novo Nordisk announced an additional $1.4 billion investment for its facility in France. The demand for these products is likely to increase in the coming years as regulators increase scrutiny of product contamination.
- Regional Supply Networks: Manufacturers can also add revenue by building pharmaceutical production facilities in North America and Europe to ensure a stable supply of pharmaceuticals, while reducing the risk of supply disruptions due to tariffs and shipping. In February 2025, the U.S. government reported 99 drug-shortage responses that involved the initiative to produce drugs domestically.
- Sustainable Manufacturing: There is an increased demand for lower-solvent processes, energy-efficient utilities, and recyclable, sustainable and low-carbon packaging to produce pharmaceutical products. Lower-solvent and continuous processes, increased automation, and use of digital twin technologies will be required to reduce reliance on long technology-transfer cycles. The European Investment Bank approved a €120 million loan to a project in April 2025, to enhance sustainability in the pharmaceutical sector. There will also be an increased demand for suppliers to invest in areas to reduce their environmental impact.
- Digital Manufacturing Services: Additional sources of recurring revenue beyond the production fee include real-time process analytics, electronic batch records, and predictive maintenance. May 2025 was a landmark month for continuous manufacturing as the FDA announced the approval of more than 20 products utilizing continuous manufacturing. Digital capability will impact the awards of contracts, and by 2025, customers will be looking for contract manufacturers with the digital capability for faster release, stronger traceability, and consistent scale-up.
Contract manufacturing of pharmaceuticals is also moving beyond capacity substitution. The highest opportunity exists at the intersection of technical complexity, regulatory burden, and supply resilience. Depending on where these intersect, supply will be regional. Providers that strategically combine these will gain a competitive edge in the long-term. Contract manufacturing of pharmaceuticals requires dependable technology transfer and quality performance. Transparent quality performance and uncomplicated technology transfer will be required by customers to differentiate from the rest.
Pharmaceutical Contract Manufacturing Market Drivers and Challenges
The pharmaceutical contract manufacturing market is being impacted by various trends such as advancements in technology, varying economic conditions, and changing expectations of the regulatory and healthcare landscape. Pharmaceutical companies choose to outsource part of their operations, in order to meet the growing demand for specialized capacity, and reduce costs. Lucintel mentions the challenges such as quality, supply-chain, and compliance risks, as the major barriers to the market.
The factors responsible for driving this market include:
- Rising Demand for Biologics: With the growing need for vaccines, monoclonal antibodies, cell therapies and other biologics, there is increasing trend towards outsourcing the specialized development and manufacturing of these products by pharmaceutical companies. Global sales of biologics exceeded USD 400 billion in 2025, demonstrating the significance of these products. Contract manufacturers with capabilities of producing sterile and high containment products are preferred. In the next three to five years, with increasing prevalence of chronic diseases and expanding clinical pipelines, there would be greater demand for manufacturing, analytical testing and fill-finish services of biologics. This would also favor contract manufacturers that have capabilities of producing temperature sensitive, small batch and complex products.
- Advancements in Technology: Innovations in manufacturing systems, equipment and processes have greatly improved reliability, flexibility and efficiency of pharmaceutical production. Digital and automated manufacturing systems helped contract manufacturers consolidate batch monitoring across facilities producing different dosage forms. In 2025, a significant number of pharmaceutical manufacturers adapted digital systems to replace a substantial part of manual records. These manufacturing systems offered better instrumentation for control and consistency in batch production. Going forward, pharmaceutical manufacturers would demand contract manufacturers provide better and faster traceability, lower deviations and produce more pharmaceutical products using integrated advanced analytics and digital systems.
- Outsourcing Preference: The pharmaceutical industry is transforming; companies are now outsourcing development, manufacturing, packaging, and testing and focusing on discovery, commercialization and access to the market. As of March 2025, the majority of emerging pharmaceutical companies outsourced the production of their products. There are a number of benefits associated with contract manufacturing including access to better and experienced workforce, established quality systems and, capacity to cater to the demands of sponsor companies without the need of constructing new manufacturing facilities. It is expected that over the next three to five years, this trend will continue. Shorter time frames for launching new products and rising development costs will drive the need for strategic alliances for sponsor companies.
- Regulatory Support: Regulatory agencies are moving to create an environment to advance manufacturing, flexible supply chains and improve the oversight of the production of pharmaceuticals and biologics. As of February 2025, regulators continued updating their guidance and expanding their inspections related to data integrity and continuity of the supply of pharmaceuticals. The focus of regulatory agencies is expected to further shift to the domestic supply and continuous pharmaceutical production. Manufacturers with the ability to meet the stringent regulatory requirements will be preferred by the pharmaceutical companies when sourcing for new alliances.
- Manufacturing Efficiency: Increased competition, margin compression, and the need to be manufacturing flexible is forcing pharmaceutical companies to use external manufacturers. There was a switch in 2025 to modular facilities and flexible production lines. These allowed better asset utilization, reduced change over times and cost, and supported production of smaller batches and variable demand. Personalized therapies and the use of combination products further added to the complexity. Optimal manufacturers will provide predictable and stable pricing, flexible capacity, and short lead times in the next 3-5 years. Lean and energy efficient facilities along with regional production will strengthen market position.
The challenges facing this market include:
- Quality and Compliance Complexity: A contract manufacturer has to ensure compliance with quality and standards across development, production and post market surveillance. There are escalating requirements for traceability, process and product controls, and monitoring which further add to the complexity. Stricter requirements for advanced and continuous processing and cybersecurity will impact the market in next 3-5 years. There will be rapid consolidation and market exit for small and underprepared companies.
- Capacity and Supply Chain Constraints: Shortages in raw materials and ingredients, coupled with the inability to manufacture certain types of components because of a lack of skilled personnel and facilities, continues to disrupt production and delays product launches. In July 2025, lead times for raw materials and components remained long. Capacity constraints are particularly challenging for the manufacture of cell therapies and injectable drugs and products requiring dedicated containment. Over the next three to five years, there may be supply-demand imbalances, particularly in some geographies, causing prices to increase and resulting in scheduling conflicts. There will continue to be a preference for suppliers who provide multi-source and/or regional manufacturing.
- Investment and Margin Pressure: There is a significant up-front capital expense for manufacturers to build compliant facilities, and there is increasing pressure on manufacturers to reduce prices. In November 2025, a number of large-scale pharmaceutical manufacturing projects still required hundreds of millions of dollars in up-front investment, creating significant financial exposure for service providers. During this time of increasing pressure on margins and costs, especially with regard to employee benefits, energy and technology, contract manufacturers, especially smaller ones, may not be able to keep up with the pressure to invest. This may result in larger manufacturers integrating farther down the supply chain and larger, more established, contract manufacturers, especially those with the capability and services to manufacture complex biologics, gaining a competitive edge.
The contract manufacturing segment of the pharmaceutical market is growing as pharma companies look for the flexibility to outsource some manufacturing. This trend will continue as demands for more advanced biologics and other technologies increase. Further, as new regulations continually evolve the pharmaceutical landscape, external manufacturing partners will be needed to help scale up and modernize manufacturing processes. The pressure to minimize costs and increase profits will be beneficial for highly capable CMOs. The need to operate effectively and efficiently will make the ability of CMOs to ensure compliance the limiting factor for growth in the pharmaceutical CMO sector in the next 3 to 5 years. Companies with advanced operating capabilities and specialized know-how will be well positioned to capitalize on the many opportunities that will be available in the evolving and complex global pharmaceutical manufacturing sector.
List of Pharmaceutical Contract Manufacturing Market Companies
Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. Through these strategies pharmaceutical contract manufacturing market companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the pharmaceutical contract manufacturing market companies profiled in this report include-
- Thermo Fisher Scientific
- Catalent
- Lonza
- Almac Group
- Recipharm
- Patheon
- Grifols International
Pharmaceutical Contract Manufacturing Market by Segment
The study includes a forecast for the global pharmaceutical contract manufacturing market by services, end use, and region.
Pharmaceutical Contract Manufacturing Market by Services [Value ($B) from 2019 to 2035]:
- Manufacturing
- Drug Development
- Biologics Manufacturing
Pharmaceutical Contract Manufacturing Market by End Use [Value ($B) from 2019 to 2035]:
- Big Pharmaceutical
- Small & Medium-Sized Pharmaceutical
- Generic Pharmaceutical
- Others
Pharmaceutical Contract Manufacturing Market by Region [Value ($B) from 2019 to 2035]:
- North America
- Europe
- Asia Pacific
- The Rest of the World
Country Wise Outlook for the Pharmaceutical Contract Manufacturing Market
Pharmaceutical contract manufacturing is changing for 2025-2027 to focus on biologics and advanced therapies with a more reliable regional supply. Many large manufacturers are investing in domestic and specialized facilities. According to Lucintel's latest report, these changes will affect outsourcing without eliminating the need for low-cost manufacturing in Asia.
- United States: Sanofi announced a $9 billion US investment to create biomanufacturing and vaccine production facilities in February 2025. This program will create commercial-scale capacity and strengthen the country's position in the outsourced biologics and critical medicines in the next 3-5 years.
- China: WuXi Biologics announced the commissioning of its 24,000-liter drug-substance facility in Ireland in January 2025 and continued to expand its Chinese capacity. By 2024, its global network had exceeded 680,000 liters of mammalian bioreactor capacity, and its integrated footprint will continue to facilitate contract manufacturing of biologics for multinationals, even with shifting trade and supply chain policies.
- Germany: In April 2025, Boehringer Ingelheim announced a €1.3 billion investment to enhance its manufacturing facilities at its biopharmaceutical site in Vienna. Germany, with the assistance of this expansion, will be one of the leading nations for high value contract development and manufacturing, as well as large-scale biologics.
- India: By March 2025, the Indian Department of Pharmaceuticals approved 48 projects under the bulk-drug production-linked incentive scheme, committing a total of ₹4,000 crore. With government support, contract manufacturers' capacity of intermediates and APIs will improve in the medium term.
- Japan: In April 2025, Fujifilm announced that its US subsidiary would spend $1.2 billion to build a manufacturing facility to provide cell culture and related services. The investment will strengthen Japan's cell therapy manufacturing capacity and provide advanced therapy manufacturing services to its partners over the next 3-5 years.
Features of the Global Pharmaceutical Contract Manufacturing Market
- Market Size Estimates: pharmaceutical contract manufacturing market size estimation in terms of value ($B).
- Trend and Forecast Analysis: Market trends (2019 to 2026) and forecast (2027 to 2035) by various segments and regions.
- Segmentation Analysis: pharmaceutical contract manufacturing market size by services, end use, and region in terms of value ($B).
- Regional Analysis: pharmaceutical contract manufacturing market breakdown by North America, Europe, Asia Pacific, and Rest of the World.
- Growth Opportunities: Analysis of growth opportunities in different services, end use, and regions for the pharmaceutical contract manufacturing market.
- Strategic Analysis: This includes M&A, new product development, and competitive landscape of the pharmaceutical contract manufacturing market.
Analysis of competitive intensity of the industry based on Porter's Five Forces model.
If you are looking to expand your business in this or adjacent markets, then contact us. We have done hundreds of strategic consulting projects in market entry, opportunity screening, due diligence, supply chain analysis, M & A, and more.
This report answers following 11 key questions:
- Q.1. What are some of the most promising, high-growth opportunities for the pharmaceutical contract manufacturing market by services (manufacturing, drug development, and biologics manufacturing), end use (big pharmaceutical, small & medium-sized pharmaceutical, generic pharmaceutical, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
- Q.2. Which segments will grow at a faster pace and why?
- Q.3. Which region will grow at a faster pace and why?
- Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
- Q.5. What are the business risks and competitive threats in this market?
- Q.6. What are the emerging trends in this market and the reasons behind them?
- Q.7. What are some of the changing demands of customers in the market?
- Q.8. What are the new developments in the market? Which companies are leading these developments?
- Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
- Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
- Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?